The UK and US have secured a significant bilateral deal that will guarantee no import taxes on British medicine products being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to boost expenditure on medicines through the NHS. This commitment guarantees that tariffs on these key exports will be held at zero for a period of the next three years.
This agreement comes after earlier warnings to hike duties on branded drug products, with increases floated as high as 100%.
"This arrangement with the UK reinforces the global environment for cutting-edge drugs and brings much-needed equity to American-British drug exports," an announcement declared.
Trade Significance
Pharmaceuticals constitute one of the UK's most significant goods shipped to the US, which is easily the biggest destination for major UK drugmakers.
Statistics show that in the one-year period leading up to the third quarter, the UK exported medicines valued at over eleven billion pounds to the US. This value accounted for a significant portion of British export trade in that period.
"This guarantee secures employment, stimulates capital expenditure and facilitates the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The pact involves several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to double overall public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. Previously, refunds were more than twenty percent.
Recent Tensions
The pact comes amid a protracted tension between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
This friction were heightened by arguments that American consumers were paying several times more for the same drugs than consumers in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been delayed or abandoned, while major funding commitments have been directed toward US facilities.
The Science Minister stated that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had declined as a percentage of its total funding over the previous ten-year period.
